Emergent BioSolutions to manufacture new anthrax vaccine

A $29 million contract between the federal government and Emergent BioSolutions ensures that the next generation of the nation's only anthrax vaccine will be made in Lansing.
According to excerpts from the article:
"The five-year contract with the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund production and other 'non-clinical functions' as the company prepares to seek approval from the U.S. Food and Drug Administration for the 'investigational new drug,' the company said earlier this month. NuThrax would be a dry version that could survive without expensive cold storage during shipping.

"At the same time, Emergent also is working to expand production of BioThrax, the only FDA-approved anthrax vaccine, at its Lansing plant."
Read the full article here.
Signup for Email Alerts

Related Company